Skip to main content

Aligos Therapeutics, Inc.

ALGS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001799448

No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.

Q4 2024 vs. Q3 2024

How the institutions holding Aligos Therapeutics, Inc. changed between Q3 2024 and Q4 2024.

All holders in Q4 2024All holders in Q3 2024

13F holders of ALGS: Q3 2024 compared with Q4 2024
MeasureQ3 2024Q4 2024Change
Holders2734+7
Shares1.69M1.62M−72.7K (−4.3%)
Value$14.7M$64.5M+$49.9M (+340.3%)

New holders (13)

Institutions that held Aligos Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.

Institutions new to ALGS in Q4 2024
InstitutionSharesValue% of portfolio
Trexquant Investment LP69,050$2.75M0.03%
Ikarian Capital, LLC64,300$2.56M0.73%
Avantax Advisory Services, Inc.30,570$1.22M0.01%
Drive Wealth Management, LLC23,000$916.3K0.22%
Royal Bank of Canada23,008$916.0K0.00%
Wells Fargo & Company21,800$868.5K0.00%
Boothbay Fund Management, LLC18,543$738.8K0.02%
State Street Corp9,582$381.7K0.00%
Northern Trust Corp5,157$205.5K0.00%
Golden State Wealth Management, LLC2,674$106.5K0.02%
Spire Wealth Management200$7.97K0.00%
SBI Securities Co., Ltd.171$6.81K0.00%
Nelson, Van Denburg & Campbell Wealth Management Group, LLC80$3.19K0.00%

Sold out (6)

Institutions that held Aligos Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.

Institutions that sold out of ALGS in Q4 2024
InstitutionShares, Q3 2024Value, Q3 2024
Armistice Capital, LLC315,095$2.73M
Woodline Partners LP91,971$796.5K
Acadian Asset Management LLC30,597$263.0K
Silverarc Capital Management, LLC26,219$227.1K
Qube Research & Technologies Ltd10,947$94.8K
CWM, LLC675$6.00K